Actinium Pharmaceuticals, Inc. announced the National Institutes of Health (NIH) awarded Actinium a Small Business Technology Transfer grant extension to support its clinical collaboration with Memorial Sloan Kettering Cancer Center (MSK) to study Iomab-ACT, Actinium's CD45-targeting radiotherapeutic, for targeted conditioning to achieve lymphodepletion therapy along with the reduction of cytokine release syndrome and neurotoxicity prior to administration of a CD19-targeted CAR-T cell therapy developed at MSK. Iomab-ACT is a next-generation, CD45-targeted conditioning agent intended to enable either lymphodepletion or reduced intensity conditioning prior to CAR-T and gene therapies with multi-indication potential. Iomab-ACT has the potential to reduce toxicities and improve patient outcomes when paired with MSK's CD19 CAR-T cell therapy in difficult to treat relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B cell lymphoma (DLBCL).

This grant will advance the ongoing study of Iomab-ACT for patients with relapsed or refractory B-ALL or DLBCL.